1. Home
  2. SHFS vs LPCN Comparison

SHFS vs LPCN Comparison

Compare SHFS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SHF Holdings Inc.

SHFS

SHF Holdings Inc.

HOLD

Current Price

$0.24

Market Cap

2.7M

Sector

Finance

ML Signal

HOLD

Logo Lipocine Inc.

LPCN

Lipocine Inc.

HOLD

Current Price

$2.31

Market Cap

19.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SHFS
LPCN
Founded
2015
1997
Country
United States
United States
Employees
41
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7M
19.1M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
SHFS
LPCN
Price
$0.24
$2.31
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
7.4M
105.8K
Earning Date
04-15-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
N/A
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$1.81
52 Week High
$9.18
$12.37

Technical Indicators

Market Signals
Indicator
SHFS
LPCN
Relative Strength Index (RSI) 26.80 48.87
Support Level N/A $2.16
Resistance Level $0.96 $2.46
Average True Range (ATR) 0.06 0.15
MACD -0.00 0.06
Stochastic Oscillator 5.87 62.90

Price Performance

Historical Comparison
SHFS
LPCN

About SHFS SHF Holdings Inc.

SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring, among others.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: